The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 64.50
Bid: 63.00
Ask: 66.00
Change: 1.00 (1.57%)
Spread: 3.00 (4.762%)
Open: 63.00
High: 66.50
Low: 61.50
Prev. Close: 63.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EMV C leads £4.2m round in 5G and SATCOM leader

29 Nov 2022 07:00

RNS Number : 8492H
NetScientific PLC
29 November 2022
 

Reach: 07.00, 29 November 2022

 

NetScientific plc

 

("NetScientific" or the "Company")

 

EMV Capital leads £4.2m investment round in Scottish 5G and SATCOM leader

 

Sofant Technologies also announces contract with Fortune Global 500 defence company

 

London, UK - 29 November 2022: NetScientific plc (AIM: NSCI), the active international holding company which invests in, develops, and commercialises life sciences/healthcare, sustainability, and technology companies, announces that it has joined an investment round led by its subsidiary EMV Capital Ltd ("EMVC"), together with Scottish Enterprise, Kelvin Capital Limited, and The Future Fund, in Edinburgh based Sofant Technologies Ltd ("Sofant"). The final close took the total joint investment round to £4.2m. This utilises the Company's capital light investment model, including c. £0.3m of investment from NetScientific through convertible loans converting at a discount into this round, and £1.6m of investment from investors introduced by EMVC, including both direct equity and convertible loans.

 

Sofant has also announced a contract with a Fortune Global 500 defence company to support the development of a next-generation tactical communication system.

 

Sofant will use the proceeds from this investment round to build a satellite communications terminal which targets mobile applications during the first half of 2023, and with commercial sales expected to begin later in the year. During the past year, Sofant has doubled the size of its team and achieved several significant technical and commercial milestones which have cleared the pathway to market.

 

Sofant is building a proprietary, highly efficient radio platform that directly addresses the most difficult challenges facing future wireless communication systems. While Sofant is targeting satellite communications and terrestrial fifth-generation (5G) telecommunications where power consumption is reduced by more than 70%, it has now also demonstrated the relevance of its technology to national security applications.

 

Dr Ilian Iliev, CEO of NetScientific and Sofant Board member, said that:

 

"We are delighted with Sofant's tremendous progress in their development roadmap. They continue to make a key contribution to the UK's space tech and telecoms sectors by developing a key component for increased resilience and energy efficiency in SatComs and other telecommunications systems.

 

"We also congratulate Sofant on their first commercial agreement with a leading defence contractor, as global awareness of the critical importance of communications to national security increases. We expect Sofant to play a significant role in future communication systems and are very pleased that its value is already recognised by industry leaders."

 

David Wither, CEO of Sofant, added:

 

"We are very pleased to have investors who understand the disruptive nature of Sofant's technology. When Sofant closed the previous funding round we told our investors we would demonstrate our core technology, which occurred in June of 2022. Sofant will use the proceeds from this investment round to build a satellite communications terminal which targets mobile applications, with commercial sales expected to begin later in the year."

 

This investment will result in the direct equity holding in Sofant by NetScientific of 1.8% at an aggregate value of £0.4m based on this funding round, in addition to EMVC's Capital Under Advisory representing 27.2%.

 

-Ends-

 

For more information, please contact:

 

NetScientific

Ilian Iliev, CEO Via Belvedere Communications

 

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel / Enzo Aliaj +44 (0)20 7220 1666

 

Belvedere Communications

John West / Llew Angus +44 (0) 203 008 6864

Email: langus@belvederepr.com

 

About NetScientific

 

NetScientific Plc ("NSCI") is an active holding Company that proactively invests in a global portfolio of companies across the healthcare, life science, ESG, and deep technology sectors. NetScientific delivers shareholder returns through a proactive and hands-on management approach to its portfolio companies; identifying, investing in, and helping to build game-changing companies. The Group targets value inflection points and the release of value through partial or full exits from trade sales, public listings, or equity sales. The Company has a strong Trans-Atlantic and growing international presence, providing attractive expansion prospects.

 

The Company differentiates itself by employing a capital-light investment approach, making use of its wholly owned subsidiary, EMV Capital's network of private, corporate, and institutional investors. By syndicating investment and making minimal use of its balance sheet, the Company is able to secure direct stakes, as well as carried interest stakes, in its portfolio. This ultimately creates a structure that can support a large portfolio with a limited balance sheet.

 

NetScientific is headquartered in London, United Kingdom, and was admitted to trading on AIM, a market operated by the London Stock Exchange, in 2013.

 

www.netscientific.net

 

About Sofant Technologies

 

Sofant Technologies is a leading-edge radio technology company based in Edinburgh, Scotland. The company is applying its proprietary RF MEMS technology to develop an extremely low power, low-cost platform which solves power consumption and heat problems in satellite communications and 5G antenna systems. Sofant employs a fabless semiconductor business model which enables it to leverage long established high-volume, low-cost production methods. This positions Sofant to offer its customers game-changing performance at a highly competitive price and guaranteed scalability.

 

www.sofant.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFFFLLLFLTFIF
Date   Source Headline
24th May 20217:00 amRNSProAxsis Update
21st May 202111:00 amRNSPrice Monitoring Extension
20th May 20214:19 pmRNSPDS Announces Release of PDS0101 Abstract
20th May 20217:00 amRNSEMV Capital Advises on £3.4m PointGrab Fundraise
18th May 20217:00 amRNSPDS receives $4.5m from net sale of tax benefits
13th May 20213:15 pmRNSPDS Reports Results for Q1 2021 & Business Update
13th May 20217:00 amRNSEMV Capital Advises on £2.9m SageTech Fundraise
30th Apr 20217:00 amRNSPDS Announces Presentation at ASCO Annual Meeting
28th Apr 202110:08 amRNSEMV Capital Advises on £740k Fundraise for Sofant
14th Apr 20212:25 pmRNSNotice of AGM and Annual Report & Accounts
31st Mar 20219:02 amRNSPreliminary Results for the year ended 31 Dec 2020
30th Mar 20217:00 amRNSNotice of Results & Investor Presentation
18th Mar 202111:48 amRNSPDS Reports Results for FY2020 & Business Update
11th Mar 20213:26 pmRNS$60m Commitment for PDS Vaccine Consortium
23rd Feb 20217:00 amRNSPDS Biotech Consortium Update
22nd Feb 20217:00 amRNSProAxsis Update
10th Feb 202111:01 amRNSPrice Monitoring Extension
10th Feb 20219:05 amRNSSecond Price Monitoring Extn
10th Feb 20219:00 amRNSPrice Monitoring Extension
5th Feb 20214:40 pmRNSSecond Price Monitoring Extn
5th Feb 20214:35 pmRNSPrice Monitoring Extension
5th Feb 20212:06 pmRNSSecond Price Monitoring Extn
5th Feb 20212:01 pmRNSPrice Monitoring Extension
5th Feb 202111:05 amRNSSecond Price Monitoring Extn
5th Feb 202111:00 amRNSPrice Monitoring Extension
3rd Feb 20212:45 pmRNSRestoration - Netscientific plc
3rd Feb 20212:45 pmRNSPDS Phase II Trial Update & Restoration of Trading
2nd Feb 20217:30 amRNSSuspension - Netscientific plc
2nd Feb 20217:00 amRNSSuspension of Trading on AIM
25th Jan 20217:00 amRNSIssue of Shares, Director/PDMR Shareholding & TVR
4th Jan 202110:31 amRNSHolding(s) in Company
21st Dec 20202:59 pmRNSPDS Announces Publication of Data by Mount Sinai
10th Dec 20207:00 amRNSProAxsis awarded Innovate UK grant
7th Dec 202011:05 amRNSSecond Price Monitoring Extn
7th Dec 202011:00 amRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSBoard changes and Grant of Options
30th Nov 20201:56 pmRNSEMV Capital leads a £1.28m investment in SageTech
19th Nov 20207:00 amRNSProAxsis appoints DiaPharma as distributor
11th Nov 20202:10 pmRNSPDS updates on Versamune based COVID-19 vaccine
10th Nov 202012:47 pmRNSPDS Biotech Initiates VERSATILE-002 Phase 2 Trial
27th Oct 20209:46 amRNSPDS Announces Initiation of PDS0101 Phase 2 Trial
16th Oct 20207:00 amRNSNetScientific acquires 100% of portfolio company
30th Sep 20209:08 amRNSDirector/PDMR Shareholding
30th Sep 20209:07 amRNSHolding(s) in Company
30th Sep 20208:58 amRNSHolding(s) in Company
25th Sep 202012:37 pmRNSGrant of Options to Director
24th Sep 20207:00 amRNSInterim Results
2nd Sep 20207:00 amRNSHolding(s) in Company
2nd Sep 20207:00 amRNSHolding(s) in Company
24th Aug 202011:28 amRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.